Geert Villeirs

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6737226/publications.pdf

Version: 2024-02-01

46	6,848	279487	264894
papers	citations	23 h-index	42 g-index

47	47	47	6361
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	ESUR prostate MR guidelines 2012. European Radiology, 2012, 22, 746-757.	2.3	2,176
2	Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. European Urology, 2019, 76, 340-351.	0.9	1,270
3	Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. Journal of Clinical Oncology, 2018, 36, 446-453.	0.8	972
4	Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. European Urology, 2015, 68, 1045-1053.	0.9	657
5	Multiparametric MRI for prostate cancer diagnosis: current status and future directions. Nature Reviews Urology, 2020, 17, 41-61.	1.9	207
6	Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions. European Urology, 2019, 75, 385-396.	0.9	200
7	ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologistsâ€™ training. European Radiology, 2020, 30, 5404-5416.	2.3	185
8	PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and MRI-directed Biopsy Pathway. Radiology, 2019, 292, 464-474.	3.6	162
9	ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer. Radiotherapy and Oncology, 2018, 127, 49-61.	0.3	157
10	Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial.. Journal of Clinical Oncology, 2020, 38, 10-10.	0.8	82
11	Factors Influencing Variability in the Performance of Multiparametric Magnetic Resonance Imaging in Detecting Clinically Significant Prostate Cancer: A Systematic Literature Review. European Urology Oncology, 2020, 3, 145-167.	2.6	75
12	Prostate Magnetic Resonance Imaging for Local Recurrence Reporting (PI-RR): International Consensus -based Guidelines on Multiparametric Magnetic Resonance Imaging for Prostate Cancer Recurrence after Radiation Therapy and Radical Prostatectomy. European Urology Oncology, 2021, 4, 868-876.	2.6	72
13	An update of pitfalls in prostate mpMRI: a practical approach through the lens of PI-RADS v. 2 guidelines. Insights Into Imaging, 2018, 9, 87-101.	1.6	69
14	What kind of prostate cancers do we miss on multiparametric magnetic resonance imaging?. European Radiology, 2016, 26, 1098-1107.	2.3	63
15	The primacy of multiparametric MRI in men with suspected prostate cancer. European Radiology, 2019, 29, 6940-6952.	2.3	51
16	The Evolution of MRI of the Prostate: The Past, the Present, and the Future. American Journal of Roentgenology, 2019, 213, 384-396.	1.0	39
17	ESUR/ESUI position paper: developing artificial intelligence for precision diagnosis of prostate cancer using magnetic resonance imaging. European Radiology, 2021, 31, 9567-9578.	2.3	34
18	Rectal toxicity after intensity modulated radiotherapy for prostate cancer: Which rectal dose volume constraints should we use?. Radiotherapy and Oncology, 2014, 113, 398-403.	0.3	28

#	Article	IF	Citations
19	Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 158.e13-158.e20.	0.8	27
20	Focus on the Quality of Prostate Multiparametric Magnetic Resonance Imaging: Synopsis of the ESUR/ESUI Recommendations on Quality Assessment and Interpretation of Images and Radiologistsâ€™ Training. European Urology, 2020, 78, 483-485.	0.9	27
21	Salvage Pelvic Lymph Node Dissection in Recurrent Prostate Cancer: Surgical and Early Oncological Outcome. BioMed Research International, 2015, 2015, 1-6.	0.9	26
22	Feasibility study using iodine quantification on dual-energy CT enterography to distinguish normal small bowel from active inflammatory Crohnâ€™s disease. Acta Radiologica, 2019, 60, 679-686.	0.5	26
23	Combining high dose external beam radiotherapy with a simultaneous integrated boost to the dominant intraprostatic lesion: Analysis of genito-urinary and rectal toxicity. Radiotherapy and Oncology, 2016, 119, 398-404.	0.3	24
24	The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) Registry. European Urology Open Science, 2021, 29, 68-76.	0.2	23
25	Diagnostic Accuracy and Observer Agreement of the MRI Prostate Imaging for Recurrence Reporting Assessment Score. Radiology, 2022, 304, 342-350.	3.6	21
26	Release of urinary extracellular vesicles in prostate cancer is associated with altered urinary N-glycosylation profile. Journal of Clinical Pathology, 2017, 70, 838-846.	1.0	18
27	How does PI-RADS v2.1 impact patient classification? A head-to-head comparison between PI-RADS v2.0 and v2.1. Acta Radiologica, 2021, 62, 839-847.	0.5	18
28	T-staging of prostate cancer: Identification of useful signs to standardize detection of posterolateral extraprostatic extension on prostate MRI. Clinical Imaging, 2020, 59, 1-7.	0.8	17
29	Imaging of distant metastases of prostate cancer. Medical Oncology, 2018, 35, 148.	1.2	16
30	Contrast Medium or No Contrast Medium for Prostate Cancer Diagnosis. That Is the Question. Journal of Magnetic Resonance Imaging, 2021, 53, 13-22.	1.9	16
31	Role of Imaging in the Diagnosis and Management of Complete Androgen Insensitivity Syndrome in Adults. Case Reports in Radiology, 2013, 2013, 1-6.	0.5	15
32	Prostate Imaging-Reporting and Data System Version 2 and the Implementation of High-quality Prostate Magnetic Resonance Imaging. European Urology, 2017, 72, 189-191.	0.9	12
33	A case report and a literature review of primary retroperitoneal mucinous cystadenoma: the importance of imaging in diagnosis and management. Future Oncology, 2018, 14, 2923-2931.	1.1	11
34	Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial. BMC Cancer, 2021, 21, 1113.	1.1	10
35	Prostate magnetic resonance spectroscopic imaging at 1.5tesla with endorectal coil versus 3.0tesla without endorectal coil: comparison of spectral quality. Clinical Imaging, 2015, 39, 636-641.	0.8	9
36	4 Weeks Versus 5ÂWeeks of Hypofractionated High-dose Radiation Therapy as Primary Therapy for Prostate Cancer: Interim Safety Analysis of a Randomized Phase 3 Trial. International Journal of Radiation Oncology Biology Physics, 2018, 100, 866-870.	0.4	7

#	Article	IF	Citations
37	Platinum Opinion Counterview: The Evidence Base for the Benefit of Magnetic Resonance Imaging-directed Prostate Cancer Diagnosis is Sound. European Urology, 2020, 78, 307-309.	0.9	7
38	Comparison of the Prostate Imaging Reporting and Data System (PI-RADS) Version 1 and 2 in a Cohort of 245 Patients with Histopathological Reference and Long-Term Follow-Up. Journal of the Belgian Society of Radiology, 2016, 100, 108.	0.2	5
39	Prostatic Leiomyoma â€“ Multiparametric Prostate MRI Features. Journal of the Belgian Society of Radiology, 2018, 102, 39.	0.1	5
40	Readressing the rationale of irradiation in stage I seminoma guidelines: a critical essay. BJU International, 2019, 124, 35-39.	1.3	4
41	The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 152.e13-152.e22.	0.8	2
42	A Curriculum Model for Multidisciplinary Training of Midwife Sonographers in a Low Resource Setting. Journal of Multidisciplinary Healthcare, 2021, Volume 14, 2833-2844.	1.1	2
43	ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologistsâ€™ training. , 2020, 30, 5404.		1
44	Editorial Comment. Urology, 2018, 113, 127-128.	0.5	0
45	Retrospective analysis of multiparametric MRI to predict complete pathologic response after neo-adjuvant chemotherapy for muscle invasive bladder cancer.. Journal of Clinical Oncology, 2021, 39, e16535-e16535.	0.8	0
46	The T1 Hemorrhage Exclusion Sign in the Detection of Prostate Cancer at MRI. Journal of the Belgian Society of Radiology, 2017, 101, 15.	0.2	0